These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 27919103)

  • 41. Naltrexone implant treatment for buprenorphine dependence--Mauritian case series.
    Jhugroo A; Ellayah D; Norman A; Hulse G
    J Psychopharmacol; 2014 Aug; 28(8):800-3. PubMed ID: 24695742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implementation of office-based buprenorphine treatment for opioid use disorder.
    Carroll E
    J Am Assoc Nurse Pract; 2021 Mar; 34(1):196-204. PubMed ID: 33767120
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Eight-hour medication-assisted treatment waiver training for opioid use disorder: integration into medical school curriculum.
    Lien IC; Seaton R; Szpytman A; Chou J; Webber V; Waineo E; Levine D
    Med Educ Online; 2021 Dec; 26(1):1847755. PubMed ID: 33222656
    [No Abstract]   [Full Text] [Related]  

  • 46. Nudging Emergency Department-Initiated Addiction Treatment.
    Butler K; Chavez T; Wakeman S; Robertson T; Leifer J; Barofsky J; Kao LS; Lefkowitz J; Dutta S; Hayes B; White B; Raja A; Martin A
    J Addict Med; 2022 Jul-Aug 01; 16(4):e234-e239. PubMed ID: 34775439
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Office-Based Addiction Treatment in Primary Care: Approaches That Work.
    Edelman EJ; Oldfield BJ; Tetrault JM
    Med Clin North Am; 2018 Jul; 102(4):635-652. PubMed ID: 29933820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Integration of Buprenorphine Treatment with Primary Care: Comparative Effectiveness on Retention, Utilization, and Cost.
    Hsu YJ; Marsteller JA; Kachur SG; Fingerhood MI
    Popul Health Manag; 2019 Aug; 22(4):292-299. PubMed ID: 30543495
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.
    Miles J; Howell J; Sheridan D; Braucht G; Mericle A
    Am J Drug Alcohol Abuse; 2020 May; 46(3):266-272. PubMed ID: 32091262
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual dilemma-should naltrexone be used in the treatment of opioid-dependent pregnant women?
    Stitzer ML
    Addiction; 2013 Feb; 108(2):249-50. PubMed ID: 23331877
    [No Abstract]   [Full Text] [Related]  

  • 51. Predictors of Medication-Assisted Treatment Initiation for Opioid Use Disorder in an Interdisciplinary Primary Care Model.
    Cantone RE; Garvey B; O'Neill A; Fleishman J; Cohen D; Muench J; Bailey SR
    J Am Board Fam Med; 2019; 32(5):724-731. PubMed ID: 31506368
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacotherapy for Substance Use Disorders.
    Klein JW
    Med Clin North Am; 2016 Jul; 100(4):891-910. PubMed ID: 27235620
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Advantages and Disadvantages of Medication-Assisted Treatment in Primary Care Offices.
    Padgett TM
    J Addict Nurs; 2019; 30(4):238-241. PubMed ID: 31800513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
    McCann DJ
    Clin Pharmacol Ther; 2008 Apr; 83(4):627-30. PubMed ID: 18212797
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
    Andrilla CHA; Moore TE; Patterson DG; Larson EH
    J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Naltrexone and opiate substitutive treatment].
    Dupouy J; Poutrain JC; Lapeyre-Mestre M
    Therapie; 2011; 66(6):549-52. PubMed ID: 22691393
    [No Abstract]   [Full Text] [Related]  

  • 57. Systematic content analysis of patient evaluations of START NOW psychotherapy reveals practical strategies for improving the treatment of opioid use disorder.
    Truong AY; Saway BF; Bouzaher MH; Rasheed MN; Monjazeb S; Everest SD; Giampalmo SL; Hartman D; Hartman C; Kablinger AS; Trestman RL
    BMC Psychiatry; 2021 Jan; 21(1):23. PubMed ID: 33423661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primary care experiences of veterans with opioid use disorder in the Veterans Health Administration.
    Jones AL; Kertesz SG; Hausmann LRM; Mor MK; Suo Y; Pettey WBP; Schaefer JH; Gundlapalli AV; Gordon AJ
    J Subst Abuse Treat; 2020 Jun; 113():107996. PubMed ID: 32359670
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implementing group visits for opioid use disorder: A case series.
    Sokol R; Albanese M; Albanese C; Coste G; Grossman E; Morrill D; Roll D; Sobieszczyk A; Schuman-Olivier Z
    Subst Abus; 2020; 41(2):174-180. PubMed ID: 31418638
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.